TNFRSF11B and Insulin resistance: RANKL inhibition through OPG, denosumab, or other RANKL inhibitors not only increased glucose uptake and attenuated subacute inflammation and insulin resistance in skeletal muscle [26] and liver [25] but also enhanced human β-cell proliferation.